NTRA - ナテラ （Natera Inc.）

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several interim analyses from ProActive, a prospective donor-derived cell-free DNA (dd-cfDNA) study evaluating Natera’s Prospera test for the detection of rejection

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several interim analyses from ProActive, a prospective donor-derived cell-free DNA (dd-cfDNA) study evaluating Natera’s Prospera test for the detection of rejection in kidney transplant patients, as well as additional presentations

Natera reported outstanding Q1 financial results, with revenues soaring to $241.8 million, marking a 24.5% increase from the same period in 2022. Read more here.

Today, we revisit genetic testing concern Natera. NTRA stock is up over 30% in 2023. Revenue growth is good, but what about profitability? Click here for more.

Invitae (NVTA) said it will appeal a verdict in a patent case in a federal court in Delaware that found in favor of Natera (NTRA). Read more here.

The following slide deck was published by Natera, Inc.

AUSTIN, Texas (AP) _ Natera Inc. (NTRA) on Thursday reported a loss of $145.2 million in its second quarter. On a per-share basis, the Austin, Texas-based company said it had a loss of $1.50. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.47 per share. The genetic testing company posted revenue of $198.2 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $194.1 million. Natera expects full-year revenue in the range of $805 million to $825 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NTRA at https://www.zacks.com/ap/NTRA

Natera press release (NTRA): Q2 GAAP EPS of -$1.50 in-line.Revenue of $198.2M (+39.5% Y/Y) beats by $4.53M.Natera anticipates 2022 total revenue of $805 million to $825 million;…

AUSTIN, Texas, Aug. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent business progress and financial outlook. Recent Accomplishments &…

Natera (NTRA) is scheduled to announce Q2 earnings results on Thursday, August 4th, after market close.The consensus EPS Estimate is -$1.50 and the consensus Revenue Estimate is…

In last trading session, Natera Inc. (NASDAQ:NTRA) saw 1.04 million shares changing hands with its beta currently measuring 1.15. Company’s recent per share price level of $35.44 trading at -$1.43 or -3.88% at ring of the bell on the day assigns it a market valuation of $3.20B. That closing price of NTRA’s stock is at … Natera Inc. (NASDAQ:NTRA) Shares Plunged -8.78% In A Week – But Will They Keep Going Up? Read More »

Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Carrier Screening Market Share, Size, Trends, Industry Analysis Report, By Type; By Medical Condition; By Technology; By End-User; By Regions; Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com''s offering. The global carrier screening market size is expected to reach USD 3.64 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth. The well-established healthcare infrastructure and the rise in innovative product introductions are driving the expansion of the industry. Many countries concentrate their efforts on developing enhanced medical infrastructure that includes enhanced treatment techniques. Furthermore, developed-country nations have modern healthcare infrastructure integrated with various transmission methods, pushing the rise and need for these techniques throughout such countries. Many people wish to discover if their genetic or inherited disorders might be transmitted to their offerings.

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Natera, Inc. (

LOS ANGELES, June 27, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ: NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of…